Page 740 - medicina-integrativa_compress

CAPÍTULO 69 PSORIASIS 755

29. Nakamura M, Toyoda M, Morohashi M: Pruritogenic mediators
BIBLIOGRAFÍA in psoriasis vulgaris: comparative evaluation of itch-associated
1. Vab de Kerkhof PCM: Psoriasis. In Bolognia JL, Jorizzo JL, Rapini cutaneous factors. Br J Dermatol 149:718-730, 2003.
RP: Dermatology. St. Louis, Mosby, 2003, pp 125-126. 30. Eillis C, Berbarian B, Sulica V, et al: A double blind evaluation
2. Li C, Scher RK: Psoriasis, nails. www.emedicine.com/derm/ of topical capsaicin in pruritic psoriasis. J Am Acad Dermatol
topic363.htm 29:438-442, 1993.
3. Espinoza LR, Cuellor ML, Silveira LH: Psoriatic arthritis. Curr Opin 31. Syed TA, Ahmad SA, Holt AH, et al: Management of psoriasis with
Rheumatol 4:470-478, 1992. aloe vera extract in a hydrophilic cream: A placebo-controlled,
4. Schroder JM, Gregory H, Young J, Christophers E: Neutrophil- double-blind study. Trop Med Int Health 1:505-509, 1996.
activating proteins in psoriasis. J Invest Dermatol 98:241-247, 1992. 32. Paulsen E, Korsholm L, Brandrup F: A double-blind, placebo-
5. Honigsmann H, Schwarz T: Ultraviolet light therapy. In Bolognia JL, controlled study of a commercial Aloe vera gel in the treatment of
Jorizzo JL, Rapini RP (eds): Dermatology. Mosby, 2003, slight to moderate psoriasis vulgaris. J Eur Acad Dermatol Venereol
pp 2109-2125. 19:326-331, 2005.
6. Honignsmann H: Phototherapy for psoriasis. Clin Exp Dermatol 33. Teelucksingh S, Mackie ADR, Burt D, et al: Potentiation of
26:343-350, 2001. hydrocortisone activity in skin by glycyrrhetinic acid. Lancet
7. Green C, Ferguson J, Lakshmipathi T, Johnson BE: 311 nm UVB 335:1060-1063, 1990.
phototherapy: An effective treatment for psoriasis. Br J Dermatol 34. Flora K, Hahn M, Rosen H, et al: Milk thistle (Silybum marianum)
119:691-696, 1988. for the therapy of liver disease. Am J Gastroenterol 93:139-143,
8. Walters IB, Burack LH, Coven TR, Gilleaudeau P, et al: 1998.
Suberythemogenic narrow-band UVB is markedly more effective 35. O’Hara M, Kiefer D, Farrell K, et al: A review of 12 commonly used
than conventional UVB in treatment of psoriasis vulgaris. J Am medicinal herbs. Arch Fam Med 7:523-536, 1998.
Acad Dermatol 40:893-900, 1999. 36. Federman DG, Froelich CW, Krisner RS: Topical psoriasis therapy.
9. Asawanonda P, et al: 308-nm excimer laser for the treatment of Am Fam Physician 59:957-962, 1999.
psoriasis: A dose-response study. Arch Dermatol 136:619-624, 2000. 37. Hessel AB, Cruz-Ramon JC, Lin AN: Agents used for treatment of
10. Stern RS, Laird N: The carcinogenic risk of treatments for severe hyperkeratosis. In Wolverton SE (ed): Comprehensive Dermatologic
psoriasis. Cancer 73:2759-2764, 1994. Drug Therapy. Philadelphia, WB Saunders, 2001, pp 676-678.
11. Runger TM: Ultraviolet light. In Bolognia JL, Jorizzo JL, Rapini RP: 38. National Psoriasis Foundation: Topical treatments: Anthralin:
Dermatology. Mosby, 2003, pp 1353-1363. http://www.psoriasis.org/treatment/psoriasis/topicals/
12. Morison WL, et al: Consensus workshop on the toxic effects of anthralin.php/
long-term PUVA therapy. Arch Dermatol 134:595-598, 1998. 39. Sachs D, Baur S, Kang S: Topical vitamin D3. In Wolverton SE (ed):
13. Stern RS, Nichols KT, Vakeva LH: Malignant melanoma in patients Comprehensive Dermatologic Drug Therapy. Philadelphia,
treated for psoriasis with methoxsalen (psoralen) and ultraviolet A WB Saunders, 2001 pp 685-694.
radiation (PUVA): The PUVA Follow-Up Study. N Engl J Med 40. Bourke JF, Mumford R, Whittaker P, et al: The effects of topical
336:1041-1045, 1997. calcipotriol on systemic calcium homeostasis in patients with
14. Harari M, Shani J: Demographic evaluation of successful chronic plaque psoriasis. J Am Acad Dermatol 37:929-934, 1997.
antipsoriatic climatotherapy at the Dead Sea DMZ clinic. Int J 41. Callen JP, Kulp-Shorten CL, Wolverton SE: Methotrexate. In
Dermatol 36:304-308, 1997. Wolverton SE (ed): Comprehensive Dermatologic Drug Therapy.
15. Knudsen E, Worm A: Psoriasis treatment at the Dead Sea [Danish]. Philadelphia, WB Saunders, 2001, pp 147-164.
Ugeskr Laeger 158:6440-6443,1996; cited by Shani J, et al: Dead-Sea 42. Lim KK, Su WP, Schroeter AL: Cyclosporine in the treatment of
climatotherapy versus other modalities of treatment for psoriasis: dermatologic disease: An update. Mayo Clin Proc 71:1182-1191,
Comparative cost-effectiveness. Int J Dermatol 38:252-262, 1999. 1996.
16. Shani J, et al: Effect of Dead Sea brine and its main salts on cell 43. Koo JYM, Lee CS, Maloney JE: Cyclosporine and related drugs.
growth in culture. Pharmacology 35:339-347, 1987. In Wolverton SE (ed): Comprehensive Dermatologic Drug Therapy.
17. Adam O, Beringer C, Kless T, et al: Anti-inflammatory effects of a Philadelphia, WB Saunders, 2001, pp 205-229.
low arachidonic acid diet and fish oil in patients with rheumatoid 44. Lebwohl M, Ali S: Treatment of psoriasis. Part 2: Systemic therapies.
arthritis. Rheumatol Int 23:27-36, 2003. J Am Acad Dermatol 45:649-661, 2001.
18. Simopoulos AP: Omega-3 fatty acids in inflammation and 45. Yamauchi PS, Rizk D, Korleimi T, et al: Current systemic therapies
autoimmune diseases. J Am Coll Nutr 21:495-505, 2002. for psoriasis: Where are we now? J Am Acad Dermatol 49:66-77,
19. Bittiner SB, Tucker WFG, Cartwright I, Bleehen SS: A double-blind, 2003.
randomized placebo controlled trial of fish oil in psoriasis. Lancet 46. Nguyen EQH, Wolverton SE: Systemic retinoids. In Wolverton SE (ed):
1(8582):378-380, 1988. Comprehensive Dermatologic Drug Therapy. Philadelphia,
20. Bjornboe A, Smith A, Bjornboe BE, et al: Effect of dietary WB Saunders, 2001, pp 269-310.
© Elsevier. Es una publicación MASSON. Fotocopiar sin autorización es un delito.
supplementation with ω-3 fatty acids on clinical manifestations of 47. Krueger G, Koo J, Lebwohl M, et al: The impact of psoriasis on
psoriasis. Br J Dermatol 118:77-83, 1988. quality of life: Results of a 1998 National Psoriasis Foundation
21. Soyland E, Funk J, Rajka G, et al: Effect of dietary supplementation patient-membership survey. Arch Dermatol 137:280-284, 2001.
with very long chain ω-3 fatty acids in patients with psoriasis. 48. Farber EM, Nall L: Psoriasis: A stress-related disease. Cutis
N Engl J Med 328:1812-1816, 1993. 51:322-326, 1993.
22. Lowe N, Borok M, Ashley J, et al: Fish oil consumption reduces 49. Sevill RH: Psoriasis and stress. Br J Dermatol 97:297-302, 1977.
hypertriglyceridemia in psoriatic patients during etretinate therapy. 50. Garg A, Chren MM, Sands LP, et al: Psychological stress perturbs
Arch Dermatol 124:177, 1988. epidermal permeability barrier homeostasis: Implications for the
23. Jellin JM, Gregory PJ, Batz F, et al: Pharmacist’s letter/Prescriber’s pathogenesis of stress-associated skin disorders. Arch Dermatol
letter. In Natural Medicines Comprehensive Database, 137:53-59, 2001.
www.naturaldatabase.com/ 51. Fortune DG, Richards HL, Kirby B, et al: Psychological distress
24. Michaelsson G, Ljunghall K: Patients with dermatitis herpetiformis, impairs clearance of psoriasis in patients treated with
acne, psoriasis and Darier’s disease have low epidermal zinc photochemotherapy. Arch Dermatol 139:752-756, 2003.
concentrations. Acta Derm Venereol 70:304-308, 1990. 52. Winchell SA, Watts RA: Relaxation therapies in the treatment of
25. McMillan EM, Rowe D: Plasma zinc in psoriasis: relation to surface psoriasis and possible pathophysiologic mechanisms. J Am Acad
area involvement. Br J Dermatol 108:301-305, 1983. Dermatol 18:101-104, 1988.
26. Burrows NP, Turnbull AJ, Punchard NA, et al: A trial of oral zinc 53. Zachariae R, Oster H, Bjerring P, et al: Effects of psychologic
supplementation in psoriasis. Cutis 54:117-118, 1994. intervention on psoriasis: A preliminary report. J Am Acad
27. Naukkarinen A, Nickoloff BJ, Farber EM: Quantification of Dermatol 34:1008-1015, 1996.
cutaneous sensory nerves and their substance P content in psoriasis. 54. Kabat-Zinn J, Wheeler E, Light T, et al: Influence of a mindfulness
J Invest Dermatol 92:126-129, 1989. meditation-based stress reduction intervention on rates of skin
28. Lotz M, Vaughan JH, Carson DA: Effect of neuropeptides on clearing in patients with moderate to severe psoriasis undergoing
production of inflammatory cytokines by human monocytes. phototherapy (UVB) and photochemotherapy (PUVA).
Science 241:1218-1221, 1988. Psychosom Med 60:625-632, 1998.